Mereo BioPharma Group plc 8K

Mereo BioPharma entered into an option and license agreement granting Sentynl Therapeutics U.S. commercial and global manufacturing rights to alvelestat for AATD-LD, with substantial potential upfront, milestone, and royalty economics contingent on option exercise.

Mereo BioPharma Group plc announced that it has entered into an option and license agreement with Sentynl Therapeutics, Inc., a subsidiary of Zydus Lifesciences, granting Sentynl an exclusive option to license U.S. commercial rights and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease, while Mereo retains rest-of-world commercial rights and will lead global Phase 3 development. During a short option period, the companies will collaborate to refine the Phase 3 trial design and advance manufacturing. Mereo will receive a non-refundable upfront option fee and, upon Sentynl’s exercise of the option, would be entitled to $40 million in upfront and R&D payments, up to $435 million in additional regulatory and commercial milestone payments, and double-digit tiered royalties on U.S. net sales, with Sentynl funding the Phase 3 program if the option is exercised and the study, potentially starting in early 2027, proceeds.

Filing Facts

CIK

1719714

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-343482

Alert Tier

7